1. Home
  2. ALXO vs MCHX Comparison

ALXO vs MCHX Comparison

Compare ALXO & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALXO
  • MCHX
  • Stock Information
  • Founded
  • ALXO 2015
  • MCHX 2003
  • Country
  • ALXO United States
  • MCHX United States
  • Employees
  • ALXO N/A
  • MCHX N/A
  • Industry
  • ALXO Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • ALXO Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • ALXO Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • ALXO 81.1M
  • MCHX 79.9M
  • IPO Year
  • ALXO 2020
  • MCHX 2004
  • Fundamental
  • Price
  • ALXO $1.41
  • MCHX $1.65
  • Analyst Decision
  • ALXO Strong Buy
  • MCHX
  • Analyst Count
  • ALXO 6
  • MCHX 0
  • Target Price
  • ALXO $14.20
  • MCHX N/A
  • AVG Volume (30 Days)
  • ALXO 886.3K
  • MCHX 38.6K
  • Earning Date
  • ALXO 11-07-2024
  • MCHX 10-31-2024
  • Dividend Yield
  • ALXO N/A
  • MCHX N/A
  • EPS Growth
  • ALXO N/A
  • MCHX N/A
  • EPS
  • ALXO N/A
  • MCHX N/A
  • Revenue
  • ALXO N/A
  • MCHX $48,594,000.00
  • Revenue This Year
  • ALXO N/A
  • MCHX N/A
  • Revenue Next Year
  • ALXO N/A
  • MCHX $4.20
  • P/E Ratio
  • ALXO N/A
  • MCHX N/A
  • Revenue Growth
  • ALXO N/A
  • MCHX N/A
  • 52 Week Low
  • ALXO $1.19
  • MCHX $1.11
  • 52 Week High
  • ALXO $17.83
  • MCHX $2.15
  • Technical
  • Relative Strength Index (RSI)
  • ALXO 47.30
  • MCHX 42.16
  • Support Level
  • ALXO $1.19
  • MCHX $1.65
  • Resistance Level
  • ALXO $1.63
  • MCHX $1.76
  • Average True Range (ATR)
  • ALXO 0.11
  • MCHX 0.12
  • MACD
  • ALXO 0.01
  • MCHX -0.01
  • Stochastic Oscillator
  • ALXO 50.00
  • MCHX 0.00

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: